# MAINE STATE LEGISLATURE

The following document is provided by the LAW AND LEGISLATIVE DIGITAL LIBRARY at the Maine State Law and Legislative Reference Library http://legislature.maine.gov/lawlib



Reproduced from electronic originals (may include minor formatting differences from printed original)



## 132nd MAINE LEGISLATURE

### FIRST REGULAR SESSION-2025

**Legislative Document** 

No. 1001

H.P. 648

House of Representatives, March 11, 2025

An Act to Prohibit Medical Providers and Certain Others from Reporting Prescribed Medication-assisted Treatment of Parents to Child Protective Services

Reference to the Committee on Health and Human Services suggested and ordered printed.

ROBERT B. HUNT Clerk

R(+ B. Hunt

Presented by Representative MILLIKEN of Blue Hill. Cosponsored by Senator BRENNER of Cumberland and

Representative: DILL of Old Town, Senator: MOORE of Washington.

#### Be it enacted by the People of the State of Maine as follows:

**Sec. 1. 22 MRSA §4004-B,** as amended by PL 2019, c. 342, §2, is further amended by enacting at the end a new paragraph to read:

If an infant is identified as affected by substance use or withdrawal symptoms from prenatal drug exposure resulting only from the parent's receiving medication-assisted treatment, as defined in section 4011-B, subsection 2, paragraph B, and there is no evidence that the infant is abused or neglected or at risk of being abused or neglected, the requirements of this section do not apply.

#### Sec. 2. 22 MRSA §4011-A, sub-§4-A is enacted to read:

- 4-A. Medication-assisted treatment. Notwithstanding any provision of law to the contrary, a person who is otherwise required under this section to report to the department any suspicion or knowledge of abuse or neglect may not report that a custodial parent, parent, foster parent or other person responsible for the child is receiving medication-assisted treatment as defined in section 4011-B, subsection 2, paragraph B if there is no suspicion that a child has been or is at risk of being abused or neglected.
- **Sec. 3. 22 MRSA §4011-B, sub-§1,** as amended by PL 2019, c. 342, §3, is further amended to read:
- 1. Notification of prenatal exposure to drugs or having a fetal alcohol spectrum disorder. A health care provider involved in the delivery or care of an infant who the provider knows or has reasonable cause to suspect has been born affected by substance use, has withdrawal symptoms that require medical monitoring or care beyond standard newborn care when those symptoms have resulted from or have likely resulted from prenatal drug exposure, whether the prenatal exposure was to legal or illegal drugs, or has a fetal alcohol spectrum disorder shall notify the department of that condition in the infant unless the infant is born to a parent who is receiving medication-assisted treatment and there is no evidence of abuse or neglect. If a health care provider notifies the department that an infant is born to a parent who is receiving medication-assisted treatment when there is no evidence of abuse or neglect, the department may not take any further action based on the notification. The notification required by this subsection must be made in the same manner as reports of abuse or neglect required by this subschapter.
  - A. This section, and any notification made pursuant to this section, may not be construed to establish a definition of "abuse" or "neglect."
  - B. This section, and any notification made pursuant to this section, may not be construed to require prosecution for any illegal action, including, but not limited to, the act of exposing a fetus to drugs or other substances.
- Sec. 4. 22 MRSA §4011-B, sub-§2, as enacted by PL 2003, c. 673, Pt. Z, §5, is repealed and the following enacted in its place:
- **2. Definitions.** As used in this section, unless the context indicates otherwise, the following terms have the following meanings.
  - A. "Health care provider" means a person described in section 4011-A, subsection 1, paragraph A, subparagraphs (1) to (10), (15), (17) to (20) or (22) or any person who

assists in the delivery or birth of a child for compensation, including, but not limited to, a midwife or provides services to a newborn child.

B. "Medication-assisted treatment" means a treatment method that consists of, or includes, medication approved by the federal Food and Drug Administration for the treatment of substance use disorder provided by a health care provider or at a methadone treatment program.

#### Sec. 5. 22 MRSA §4011-B, sub-§3 is enacted to read:

3. Develop plan for safe care. For an infant who a health care provider knows or has reasonable cause to suspect has been born affected by substance use or has withdrawal symptoms that require medical monitoring or care beyond standard newborn care due to the parent's receiving medication-assisted treatment, but when there is no evidence of abuse or neglect, the health care provider shall develop a plan for the safe care of the infant and, in appropriate cases, refer the infant or parent or both to a social service agency or another health care provider for any required services.

15 SUMMARY

This bill modifies the requirements for notification to the Department of Health and Human Services when an infant is born affected by substance use or has withdrawal symptoms that require medical monitoring or care beyond standard newborn care when those symptoms have resulted from or have likely resulted from prenatal drug exposure. If the infant is affected by substances because the infant is born to a person who is receiving medication-assisted treatment but there is no apparent risk of abuse or neglect, the health care provider may not notify the department and must develop a plan of care for the infant. If the health care provider notifies the department anyway, the department may not take further action. The bill also prohibits a mandated reporter from notifying the department that a parent or other person responsible for the child is receiving medication-assisted treatment when there is no suspicion of abuse or neglect.